Forbion Capital to sell Santaris Pharma to Roche for up to $450 mln

Forbion Capital Partners has sold biopharmaceutical company Santaris Pharma A/S for $450 million to Roche. The deal is structured with an upfront cash payment of $250 million and additional contingent payments of up to $200 million based on achievement of certain milestones.

North AmericaUSBriefs